Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

Pharmacy benefit managers steer Medicare patients to use their own pharmacies

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies.

10 Jan 2025

Study highlights gender inequality in lung transplantation access and outcomes

Women are less likely to receive a lung transplant and spend an average of six weeks longer on the waiting list, according to a study published today (Thursday) in ERJ Open Research.

8 Jan 2025

AI-designed drug shows promise for inflammatory bowel disease

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico's Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).

8 Jan 2025

Inogen receives FDA 510(k) clearance for SIMEOX 200 airway clearance device

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, expanding the company’s ability to market and meet the various needs of patients with chronic respiratory diseases in the U.S.

6 Jan 2025

Y chromosome’s unexpected impact on aging and disease in men

Loss of the Y chromosome (LOY) in men, a dynamic mutation linked to aging, impairs immune function and increases risks of cancer, Alzheimer’s, and cardiovascular diseases, making it a promising biomarker and therapeutic target.

5 Jan 2025

Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative PRMT5 inhibitor with AI-powered novel scaffold, as preclinical candidate (PCC) for the treatment of MTAP-deleted cancers.

2 Jan 2025

Dextromethorphan found to have potential in treating lung fibrosis

A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.

22 Dec 2024

Shiitake-based supplement may help prevent liver damage progression

AHCC demonstrates potential in preventing liver fibrosis progression by inhibiting HSC activation and regulating key pathways involved in liver injury.

20 Dec 2024

Long-term green tea catechins prevent aging-related cardiac dysfunction

A new publication from Genes & Diseases; DOI 10.1016/j.gendis.2024.101284, discusses the effect of long-term administration of green tea catechins on aging-related cardiac diastolic dysfunction and decline of troponin I.

20 Dec 2024

Understanding the mechanisms behind alcohol-associated liver disease

A newly published review in eGastroenterology compiles recent research on alcohol-associated liver disease (ALD), offering an overview of its pathogenesis and efforts to better understand this condition.

19 Dec 2024

AHCC supplement shows potential in protecting the liver from fibrosis

Chronic liver damage can lead to hepatitis, which causes fibrosis of the liver. This buildup of collagen and other fibrous tissue accelerates when hepatic stellate cells become activated during hepatitis, often resulting in liver cancer or cirrhosis, both of which can be fatal.

19 Dec 2024

Cough syrup ingredient may help combat lung fibrosis

A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.

18 Dec 2024

New therapies and technologies provide hope for age-related fertility challenges

Scientists explore emerging strategies to combat reproductive aging, highlighting promising therapies and technologies to improve fertility in later life.

17 Dec 2024

Dual screening for liver fibrosis and retinopathy in type 2 diabetes

Retina scanning with vibration-controlled transient elastography could predict metabolic dysfunction-associated steatotic liver disease.

17 Dec 2024

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

A novel approach to prevent severe liver disease in diabetes

New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening for eye disease. The study is published in Lancet Gastroenterology and Hepatology.

13 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

New study identifies potential target for treating diabetic cardiomyopathy

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.

12 Dec 2024